Evidence map›Paper›PMID 42587052›Full record

Trial reportNature medicine2026

First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.

Xiying Shao, Can Tian, Zhanhong Chen, Jian Huang, Yongsheng Wang, Tao Sun, Tienan Yi, Yifen Wu, Weihua Sun, Xufang Yu and 5 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiying Shao *Zhejiang Cancer Hospital, Hangzhou, China.
Can Tian *Hunan Provincial Tumor Hospital, Changsha, China.
Zhanhong ChenZhejiang Cancer Hospital, Hangzhou, China.
Jian HuangZhejiang Cancer Hospital, Hangzhou, China.
Yongsheng WangAffiliated Cancer Hospital of Shandong First Medical University, Jinan, China.
Tao SunLiaoning Cancer Hospital and Institute, Shenyang, China.ORCID http://orcid.org/0000-0001-5931-386X
Tienan YiXiangyang Central Hospital, Xiangyang, China.
Yifen WuDongguan People's Hospital, Dongguan, China.
Weihua SunHuaihua Central Hospital, Huaihua, China.
Xufang YuAkeso Biopharma, Zhongshan, China.
Zhongmin Maxwell WangAkeso Biopharma, Zhongshan, China.ORCID http://orcid.org/0000-0002-1683-5147
Baiyong LiAkeso Biopharma, Zhongshan, China.
Yu XiaAkeso Biopharma, Zhongshan, China.
Xiaojia WangZhejiang Cancer Hospital, Hangzhou, China. wxiaojia0803@163.com.ORCID http://orcid.org/0000-0002-7005-0842
Quchang OuyangHunan Provincial Tumor Hospital, Changsha, China. oyqc1969@126.com.ORCID http://orcid.org/0000-0003-1233-6081

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer is an aggressive subtype comprising 10-20% of all breast cancer cases and has a worse prognosis than other subtypes. This open-label, multicenter, single-arm, phase 2 clinical trial evaluates the safety and efficacy of ivonescimab combined with chemotherapy as first-line treatment in female patients with locally advanced unresectable or metastatic triple-negative breast cancer who have not received previous systemic therapy. Eligible patients received ivonescimab 20 mg kg

Indexed as

Antibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsProgrammed Cell Death 1 ReceptorTriple Negative Breast NeoplasmsVascular Endothelial Growth Factor AAdultAgedFemaleHumansMiddle AgedPaclitaxelAntibodies, BispecificPaclitaxelPDCD1 protein, humanProgrammed Cell Death 1 ReceptorVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID42587052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.